Is time from diagnosis to radical prostatectomy associated with oncological outcomes?
- PMID: 30483947
- DOI: 10.1007/s00345-018-2570-6
Is time from diagnosis to radical prostatectomy associated with oncological outcomes?
Abstract
Purpose: To study the association between time from diagnosis to radical prostatectomy (RP-interval) and prostate cancer-specific mortality (PCSM), histological findings in the RP-specimen and failure after RP (RP-failure).
Methods: Patients diagnosed with non-metastatic prostate cancer (PCa) in 2001-2010 and prostatectomized within 180 days of biopsy were identified in the Cancer Registry of Norway and the Norwegian Prostate Cancer Registry. Patients were stratified according to risk groups and RP-intervals of 0-60, 61-90, 91-120 and 121-180 days. Aalen-Johansen and Kaplan-Meier methods estimated curves for PCSM, RP-failure and overall mortality. Multivariable Cox regressions and Chi-square tests were used to evaluate the impact of RP-interval on outcomes.
Results: In 5163 eligible patients, the median time from diagnosis to RP was 93 days (range 1-180). Risk group distribution was similar in all RP-interval groups. With almost eight years of observation, no association was found between RP-interval and PCSM in the intermediate-or high-risk groups. Increasing RP-interval did not increase the rate of adverse histological outcomes or incidence of RP-failure.
Conclusions: Increasing RP-interval up to 180 days was not associated with adverse oncological outcomes at eight years follow-up. These findings should be considered when planning for prostatectomy.
Keywords: Mortality; Outcomes; Prostate cancer; Radical prostatectomy; Timing.
Comment in
-
Prostatakarzinom: Wieviel Zeit darf bis zur Operation vergehen?Aktuelle Urol. 2020 Apr;51(2):97-98. doi: 10.1055/a-1017-7521. Epub 2020 Mar 24. Aktuelle Urol. 2020. PMID: 32208507 Review. German. No abstract available.
Similar articles
-
Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review.World J Urol. 2021 Nov;39(11):4085-4099. doi: 10.1007/s00345-021-03703-8. Epub 2021 May 28. World J Urol. 2021. PMID: 34047825 Free PMC article.
-
Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.Surg Oncol. 2017 Mar;26(1):21-27. doi: 10.1016/j.suronc.2016.12.002. Epub 2016 Dec 8. Surg Oncol. 2017. PMID: 28317581
-
Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.Eur Urol Focus. 2019 May;5(3):425-432. doi: 10.1016/j.euf.2017.12.005. Epub 2018 Jan 3. Eur Urol Focus. 2019. PMID: 29306730
-
Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.Prostate. 2018 Jun;78(9):676-681. doi: 10.1002/pros.23511. Epub 2018 Mar 23. Prostate. 2018. PMID: 29570821
-
Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?BJU Int. 2019 Aug;124(2):282-289. doi: 10.1111/bju.14671. Epub 2019 Feb 10. BJU Int. 2019. PMID: 30653804
Cited by
-
Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance.JAMA Netw Open. 2025 Jan 2;8(1):e2454366. doi: 10.1001/jamanetworkopen.2024.54366. JAMA Netw Open. 2025. PMID: 39820695 Free PMC article.
-
Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review.World J Urol. 2021 Nov;39(11):4085-4099. doi: 10.1007/s00345-021-03703-8. Epub 2021 May 28. World J Urol. 2021. PMID: 34047825 Free PMC article.
-
Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment.PLoS One. 2022 Jun 14;17(6):e0269827. doi: 10.1371/journal.pone.0269827. eCollection 2022. PLoS One. 2022. PMID: 35700180 Free PMC article.
-
Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016.BMC Cancer. 2022 Feb 28;22(1):220. doi: 10.1186/s12885-022-09306-9. BMC Cancer. 2022. PMID: 35227226 Free PMC article.
-
The role of fatal family history and mode of inheritance in prostate cancer for long-term outcomes following radical prostatectomy.World J Urol. 2020 Dec;38(12):3091-3099. doi: 10.1007/s00345-020-03147-6. Epub 2020 Mar 11. World J Urol. 2020. PMID: 32161996 Free PMC article.
References
-
- Cancer Registry of Norway (2017) Annual Report 2016 with Results and Improvements from the Norwegian Prostate Cancer Registry. https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/a... . Accessed Oct 2018
-
- Mottet N, Bellmunt J, Bolla M et al (2017) Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003 - DOI - PubMed - PMC
-
- Neal RD, Tharmanathan P, France B et al (2015) Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer 112(Suppl 1):S92–S107. https://doi.org/10.1038/bjc.2015.48 - DOI - PubMed - PMC
-
- Bruins HM, Aben KK, Arends TJ, Heijden AG, Witjes AJ (2016) The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: a Netherlands Cancer Registry analysis. Urol Oncol 34(4):e161–e166. https://doi.org/10.1016/j.urolonc.2015.11.006 - DOI
-
- Jensen AR, Nellemann HM, Overgaard J (2007) Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol 84(1):5–10. https://doi.org/10.1016/j.radonc.2007.04.001 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical